{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B2", "query": { "intervention": "Cohort B2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T00:11:47.442Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05651932", "title": "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma", "Myeloma Multiple" ], "interventions": [ { "name": "Cohort A1 & A2: KTX-1001", "type": "DRUG" }, { "name": "Cohort B1 & B2: KTX-1001+Mezigdomide", "type": "DRUG" }, { "name": "Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)", "type": "DRUG" }, { "name": "Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-02-22", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 17, "location_summary": "San Francisco, California • Jacksonville, Florida • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651932" }, { "nct_id": "NCT06617546", "title": "SAD and MAD Study of FTX-101 in Healthy Male Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "FTX-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Find Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "MALE", "summary": "18 Years to 59 Years · Male only" }, "enrollment_count": 49, "start_date": "2024-10-14", "completion_date": "2025-04-17", "has_results": false, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06617546" }, { "nct_id": "NCT01767454", "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2013-02-12", "completion_date": "2015-09-04", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767454" }, { "nct_id": "NCT07086768", "title": "Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "BSI-082", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lei Zheng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2026-01-26", "completion_date": "2028-08-07", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07086768" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT07082868", "title": "A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma (PCNSL)", "Primary Central Nervous System Lymphoma", "Relapsed Primary Central Nervous System Lymphoma", "Refractory Primary Central Nervous System Lymphoma", "Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma (SCNSL)" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-08-13", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07082868" }, { "nct_id": "NCT05205161", "title": "A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "AZD0466", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 7, "start_date": "2022-07-05", "completion_date": "2023-08-17", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05205161" }, { "nct_id": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "MEDI5752", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "AZD2936", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 175, "start_date": "2018-12-27", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819465" }, { "nct_id": "NCT06239116", "title": "A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hypothalamic Obesity", "Prader-Willi Syndrome", "PWS" ], "interventions": [ { "name": "Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)", "type": "DRUG" }, { "name": "Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)", "type": "DRUG" }, { "name": "Part C: RM-718", "type": "DRUG" }, { "name": "Part D: RM-718", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2024-03-05", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239116" }, { "nct_id": "NCT05625529", "title": "ExoLuminate Study for Early Detection of Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreas Cancer", "Exosomes", "Extracellular Vesicles", "Pancreatic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "Biological Dynamics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2022-12-19", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-09-04T00:11:47.442Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625529" } ] }